Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4760928 | 0.91 | KMT2A (0.37) | ALDH1A1PKMKMT2AMEN1BRD4 | |
| SCHEMBL1206417 | 0.88 | MEN1 (0.32) | ALDH1A1KMT2AMEN1BRD4 | |
| SCHEMBL2497098 | 0.84 | ADORA2A (0.37) | ALDH1A1SMN1; SMN2KMT2AMEN1TLR8 | |
| SCHEMBL15333396 | 0.84 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2KDM4ENPC1PKM | |
| SCHEMBL23043387 | 0.75 | LTA4H (0.43) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL1206348 | 0.75 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2KMT2AMEN1TLR8 | |
| SCHEMBL5655364 | 0.74 | TLR8 (0.57) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL14901265 | 0.74 | DUT (0.42) | KMT2AMEN1 | |
| SCHEMBL9535005 | 0.73 | TLR8 (0.56) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL27968081 | 0.73 | TLR8 (0.56) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334377-B2 | Porphyrin catalysts and methods of use thereof | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334377-B2 | Porphyrin catalysts and methods of use thereof | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334377-B2 | Porphyrin catalysts and methods of use thereof | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-12-18 | — | — | US | disclosed |
| US-20110306584-A1 | Porphyrin Catalysts and Methods of Use Thereof | TRUSTEES OF PRINCETON (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306584-A1 | Porphyrin Catalysts and Methods of Use Thereof | TRUSTEES OF PRINCETON (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306584-A1 | Porphyrin Catalysts and Methods of Use Thereof | TRUSTEES OF PRINCETON (US) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306584-A1 | Porphyrin Catalysts and Methods of Use Thereof | PPOX, POR, MPO | ALDH1A1 1190/4885SMN1; SMN2 3954/4885KDM4E 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.